Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Killeen

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Frontiers in Neurology|March 3, 2018
Cerebrospinal Fluid Presepsin As a Marker of Nosocomial Infections of the Central Nervous System: A Prospective Observational StudySergey A Abudeev, Kirill V Kiselev, Nikolay M Kruglyakov, et al.
Nature Communications|May 12, 2026
Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injuryLynn Farner, Paulina S Scheuren, Kiomars Sharifi, et al.
The Lancet. Neurology|December 20, 2024
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trialNorbert Weidner, Rainer Abel, Doris Maier, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Frontiers in Neurology|March 3, 2018
Cerebrospinal Fluid Presepsin As a Marker of Nosocomial Infections of the Central Nervous System: A Prospective Observational StudySergey A Abudeev, Kirill V Kiselev, Nikolay M Kruglyakov, et al.
Nature Communications|May 12, 2026
Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injuryLynn Farner, Paulina S Scheuren, Kiomars Sharifi, et al.
The Lancet. Neurology|December 20, 2024
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trialNorbert Weidner, Rainer Abel, Doris Maier, et al.
Pageof 5